|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.01 CNY | -0.41% |
|
+2.47% | +5.26% |
| 12-02 | Zhejiang Jolly Pharmaceutical to raise fund via bonds issuance | RE |
| 25-10-27 | Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 | CI |
| Capitalization | 11.76B 1.69B 1.45B 1.35B 1.26B 2.34B 153B 2.51B 15.53B 6.12B 73.07B 6.33B 6.2B 267B | P/E ratio 2025 * |
18.3x | P/E ratio 2026 * | 14.9x |
|---|---|---|---|---|---|
| Enterprise value | 11.76B 1.69B 1.45B 1.35B 1.26B 2.34B 153B 2.51B 15.53B 6.12B 73.07B 6.33B 6.2B 267B | EV / Sales 2025 * |
3.56x | EV / Sales 2026 * | 2.92x |
| Free-Float |
72.13% | Yield 2025 * |
4.48% | Yield 2026 * | 5.72% |
| 1 day | -0.41% | ||
| 1 week | +2.47% | ||
| Current month | +5.26% | ||
| 1 month | +0.83% | ||
| 3 months | -8.79% | ||
| 6 months | -8.05% | ||
| Current year | +5.26% |
| 1 week | 16.63 |  | 17.2 |
| 1 month | 16.16 | | 17.38 |
| Current year | 16.19 | | 17.2 |
| 1 year | 14.06 | | 21.07 |
| 3 years | 8.36 | | 21.07 |
| 5 years | 5.5 | | 21.07 |
| 10 years | 3.33 | | 21.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tao Wang
CEO | Chief Executive Officer | 58 | 2018-01-15 |
Li Ye
DFI | Director of Finance/CFO | 51 | 2022-04-17 |
Yue Hong Shen
PRN | Corporate Officer/Principal | 51 | 2021-01-24 |
| Director | Title | Age | Since |
|---|---|---|---|
You Qiang Yu
CHM | Chairman | 64 | 2003-08-26 |
Xue Gen Zheng
BRD | Director/Board Member | 61 | 2014-03-09 |
Jian Jun Wang
BRD | Director/Board Member | 57 | 2017-01-12 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.41% | +2.47% | +13.10% | +61.85% | 1.69B | |
| +0.64% | -3.58% | -15.94% | -31.90% | 6.12B | |
| -0.20% | -1.64% | -21.78% | +17.71% | 4.53B | |
| +0.46% | -3.93% | +51.42% | +48.28% | 4.38B | |
| -0.96% | -2.01% | +11.43% | -39.04% | 4.21B | |
| +0.72% | +1.15% | -5.97% | -6.70% | 3.47B | |
| +0.33% | -1.37% | +6.26% | +31.99% | 3.23B | |
| +2.00% | +1.51% | +9.78% | -19.40% | 2.5B | |
| -0.33% | -0.69% | +16.43% | +4.23% | 1.99B | |
| -0.29% | -1.88% | -1.56% | +50.76% | 1.69B | |
| Average | +0.20% | -0.75% | +6.32% | +11.78% | 3.38B | |
| Weighted average by Cap. | +0.23% | -1.18% | +4.54% | +4.82% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.3B 474M 407M 378M 353M 657M 43.04B 706M 4.36B 1.72B 20.5B 1.78B 1.74B 74.91B | 4.02B 577M 496M 460M 430M 801M 52.45B 860M 5.31B 2.09B 24.98B 2.16B 2.12B 91.3B |
| Net income | 650M 93.35M 80.17M 74.43M 69.52M 129M 8.48B 139M 859M 338M 4.04B 350M 343M 14.76B | 802M 115M 98.86M 91.78M 85.73M 160M 10.46B 171M 1.06B 417M 4.98B 432M 423M 18.2B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-19 | 16.96 ¥ | -0.29% | 8,380,334 |
| 26-01-16 | 17.01 ¥ | -0.41% | 11,435,550 |
| 26-01-15 | 17.08 ¥ | +1.07% | 12,706,800 |
| 26-01-14 | 16.90 ¥ | -0.06% | 23,283,770 |
| 26-01-13 | 16.91 ¥ | +1.68% | 23,815,520 |
End-of-day quote Shenzhen S.E., January 15, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 300181 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition